Wegovy is the brand name for semaglutide prescribed for chronic weight management. It belongs to a class of medications called GLP-1 receptor agonists, which mimic a natural gut hormone that regulates appetite and blood sugar. The FDA has approved Wegovy for adults and adolescents with obesity, or with overweight plus a weight-related health condition. It is given as a once-weekly injection, and an oral semaglutide tablet for weight management was also approved in late 2025. Wegovy uses a higher dose of semaglutide than Ozempic, which is FDA-approved for type 2 diabetes, though both share the same active ingredient.
Beyond weight management, Wegovy is FDA-approved to reduce cardiovascular risk in adults with obesity or overweight and established heart disease, and for noncirrhotic MASH, a form of fatty liver disease. What makes Wegovy relevant to families exploring addiction treatment is newer, still-emerging science about GLP-1 receptors in the brain. These receptors sit within the mesolimbic dopamine reward system, the same circuitry involved in cravings and substance use. Researchers are now studying whether semaglutide, the molecule inside Wegovy, might help quiet those reward signals. This use remains investigational and is not an FDA-approved indication for addiction.
How Does Wegovy Relate To The Brain’s Reward System?
GLP-1 receptors are found not only in the gut and pancreas but also in brain regions that govern motivation, pleasure, and craving, including the mesolimbic dopamine pathway. This is the same circuitry that becomes dysregulated in substance use disorders, where dopamine signaling drives the pull toward alcohol or drugs. Because semaglutide activates GLP-1 receptors throughout the body, including in these reward centers, scientists have begun asking whether it might dampen craving signals the way it dampens food cravings.
This connection is why Wegovy and other semaglutide medications have drawn attention from addiction researchers, even though Wegovy itself is approved only for weight management and related cardiometabolic conditions. Any exploration of semaglutide for cravings related to alcohol or other substances would currently be off-label and should only happen under close medical supervision as part of a broader, individualized treatment plan.
What Does The Research Say About Semaglutide And Addiction?
Semaglutide is the most studied GLP-1 medication in addiction research to date. A 2026 randomized controlled trial published in The Lancet found that once-weekly semaglutide, added to cognitive behavioral therapy, reduced heavy-drinking days among adults with alcohol use disorder and obesity compared with therapy alone. Large real-world population studies have separately linked semaglutide use to lower rates of diagnosed alcohol use disorder and other substance use disorders, though these studies cannot prove cause and effect the way a controlled trial can.
For families and patients, the honest picture is one of promising but early evidence. Wegovy is not an approved addiction treatment, and it does not replace counseling, medical detox, or peer support. The most common side effects reported with semaglutide are gastrointestinal, such as nausea and constipation. Anyone curious about this research should discuss it with a physician who understands both their metabolic health and their recovery goals before considering any off-label use.
Frequently Asked Questions
What is Wegovy used for?
Wegovy is the semaglutide brand approved by the FDA for chronic weight management in adults and adolescents with obesity, or with overweight and a weight-related condition. It is given as a once-weekly injection, and an oral tablet form was approved in late 2025. Wegovy is also approved to lower cardiovascular risk in adults with obesity or overweight and existing heart disease, and to treat noncirrhotic MASH, a fatty liver condition, alongside diet and exercise changes.
Is Wegovy the same medication as Ozempic?
Wegovy and Ozempic both contain semaglutide, so they are the same underlying molecule, but they are approved for different uses and dosing. Ozempic is FDA-approved for type 2 diabetes and typically uses lower doses, while Wegovy is approved specifically for chronic weight management at a higher maintenance dose. Rybelsus is a third semaglutide brand, taken as a daily oral tablet for diabetes. A person’s diagnosis and treatment goals determine which brand a physician prescribes.
Can Wegovy help treat addiction or substance use disorder?
Not officially. Wegovy is not FDA-approved for addiction, and any use for cravings related to alcohol or drugs would be off-label. Research is encouraging, including a 2026 Lancet trial showing semaglutide plus cognitive behavioral therapy reduced heavy-drinking days in adults with alcohol use disorder and obesity, and real-world data linking semaglutide to lower substance use disorder rates. This is educational information only, not medical advice, and any decision should involve a physician.
